Publication Abstract from PubMed
FAK and FGFR2 signaling pathways play important roles in cancer development, progression and tumor angiogenesis. PHM16 is a novel ATP competitive inhibitor of FAK and FGFR2. To evaluate the therapeutic efficacy of this agent, we examined its anti-angiogenic effect in HUVEC and its anti-tumor effect in different cancer cell lines. We showed PHM16 inhibited endothelial cell viability, adherence and tube formation along with the added ability to induce endothelial cell apoptosis. This compound significantly delayed tumor cell growth. Together, these data showed that inhibition of both FAK and FGFR2 signaling pathways can enhance anti-tumor and anti-angiogenic activities.
Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities.,Dao P, Jarray R, Smith N, Lepelletier Y, Coq JL, Lietha D, Hadj-Slimane R, Herbeuval JP, Garbay C, Raynaud F, Chen H Cancer Lett. 2014 Mar 19. pii: S0304-3835(14)00152-9. doi:, 10.1016/j.canlet.2014.03.007. PMID:24657306[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
